stockrowBaxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.
- Revenue
- +4.97%
- EPS
- +731.9%
- Free cash flow
- +255.6%
- Total debt
- −9.48%
Quarter to September 2026, against a year earlier
Follow BAX
Alert me
Baxter International Inc. (BAX) EPS (diluted)
Baxter International Inc.'s EPS (diluted) for fiscal 2025 was −$1.87, compared with −$1.27 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.41. Over the past ten years it has ranged from −$4.83 (fiscal 2022) to $9.01 (fiscal 2016); the current reading is higher than 18% of that period. Baxter International Inc. ranks 39th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.87 | — |
| FY2024 | −$1.27 | — |
| FY2023 | $5.25 | — |
| FY2022 | −$4.83 | — |
| FY2021 | $2.53 | 18.78% |
| FY2020 | $2.13 | 10.36% |
| FY2019 | $1.93 | (35.02%) |
| FY2018 | $2.97 | 175.00% |
| FY2017 | $1.08 | (88.01%) |
| FY2016 | $9.01 | 411.93% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.57 | 135.58% |
| Jun 2026 | $0.24 | — |
| Mar 2026 | −$0.03 | — |
| Dec 2025 | −$2.19 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| WST West Pharmaceutical Services, Inc. compare | $8.91 |
| ALGN Align Technology, Inc. compare | $6.87 |
| ATR AptarGroup, Inc. compare | $4.12 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| SOLV Solventum Corporation compare | $0.89 |
| AVTR Avantor, Inc. compare | $0.50 |
| RGEN Repligen Corporation compare | −$0.21 |
| BLCO Bausch + Lomb Corporation compare | −$0.30 |
| BAX Baxter International Inc. | −$1.41 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BAX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement